Table 1. Patient characteristics at initiation of second line vinflunine in the eligible patients.
| No Cisplatin | Prior cisplatin | Total | |
|---|---|---|---|
| N (%) | N (%) | N (%) | |
|
Age (years) |
N=106
68.85
(39.55–86.29) |
N=251
62.48
(34.58–82.92 |
N=357
64.27
(34.58–86.29) |
|
Gender | |||
| Male | 85 (80.19) | 194 (77.29) | 279 (78.15) |
| Female |
21 (19.81) |
57 (22.71) |
78 (21.85) |
|
Refractory status | |||
| Refractory patient | 11 (10.38) | 34 (13.55) | 45 (12.61) |
| Non-refractory patient |
95 (89.62) |
217 (86.45) |
312 (87.39) |
|
Liver involvement | |||
| No | 60 (56.60) | 188 (74.90) | 248 (69.47) |
| Yes |
46 (43.40) |
63 (25.10) |
109 (30.53) |
|
Number of organ(s) involved | |||
| 1 | 26 (24.53) | 60 (23.90) | 86 (24.09) |
| >1 |
80 (75.47) |
191 (76.10) |
271 (75.91) |
|
Visceral involvement | |||
| Yes | 80 (75.47) | 187 (74.50) | 267 (74.79) |
| No |
26 (24.53) |
64 (25.50) |
90 (25.21) |
|
Lymph nodes involvement | |||
| No | 42 (39.62) | 88 (35.06) | 130 (36.41) |
| Yes |
64 (60.38) |
163 (64.94) |
227 (63.59 |
|
WHO PS | |||
| PS⩾1 | 81 (76.42) | 165 (65.74) | 246 (68.91) |
| PS=0 |
25 (23.58) |
86 (34.26) |
111 (31.09) |
|
Creatinine clearance (median) |
N=105
55
(21–139) |
N=249
64.2
(23–149) |
N=354
61
(21–149) |
|
Haemoglobin | |||
| <10 g dl−1 | 14 (13.21) | 38 (15.14) | 52 (14.57) |
| ⩾10 g dl−1 |
92 (86.79) |
213 (84.86) |
305 (85.43) |
|
Alkaline phosphatase | |||
| Missing | 3 (2.83) | 6 (2.39) | 9 (2.52) |
| Abnormal | 42 (39.62) | 65 (25.90) | 107 (29.97) |
| Normal |
61 (57.55) |
180 (71.71) |
241 (67.51) |
|
Pelvic irradiation | |||
| No | 82 (77.36) | 194 ((77.29) | 276 (77.31) |
| Yes |
24 (22.64) |
57 (22.71) |
81 (22.69) |
| Number of patients | 106 (100) | 251 (100) | 357 (100) |